AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26573461 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (no SLV-I)
Number of subjects: 18410
Study 23160038 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tooth (dehydrated)
Number of subjects: 20
Study 23160038 — intervention group
Group type: COMPARATOR
Intervention: Control tooth (not dehydrated)
Number of subjects: 20
Study 23160038 — intervention group
Group type: COMPARATOR
Intervention: Panel assessment of test and control teeth
Number of subjects: 20
Study 19844185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 1720
Study 19844185 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 1720
Study 18216044 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based influenza immunization program
Number of subjects: 0
Study 18216044 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiologically based influenza immunization policy
Number of subjects: 0
Study 15985589 — intervention group
Group type: EXPERIMENTAL
Intervention: Early withdrawal of antiepileptic drugs
Number of subjects: 0
Study 12857695 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-hour longitudinal residents-as-teachers curriculum
Number of subjects: 23
Study 12857695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 10543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 5 mg twice daily
Number of subjects: 253
Study 10543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice daily
Number of subjects: 253
Study 10543667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normotensive)
Number of subjects: 253
Study 10543667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hypertensive)
Number of subjects: 253
Study 8677941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (natural alpha-interferon, 6 MU daily for 2 weeks, then 3 times a week for 22 weeks)
Number of subjects: 63
Study 8677941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (natural alpha-interferon, 6 MU daily for 8 weeks, then 2 times a week for 12 weeks)
Number of subjects: 63
Study 1723446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 22
Study 1723446 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study 7337197 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% relative humidity (RH)
Number of subjects: 0
Study 7337197 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% relative humidity (RH)
Number of subjects: 0
Study 7337197 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% relative humidity (RH)
Number of subjects: 0
Study 7337197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry air
Number of subjects: 0
Study 7337197 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid air
Number of subjects: 0
Study 7337197 — intervention group
Group type: COMPARATOR
Intervention: 50% relative humidity (RH) for both tests
Number of subjects: 0
Study 29993146 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (ALA 20% incubated 1.5 hours before red light irradiation with 37 J/cm2 fluence)
Number of subjects: 46
Study 29993146 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg/d plus adapalene gel 0.1%
Number of subjects: 46
Study 28012272 — intervention group
Group type: EXPERIMENTAL
Intervention: PBAC score at 12 months follow-up
Number of subjects: 900
Study 28012272 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PBAC score
Number of subjects: 900
Study 25201350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patsari stove
Number of subjects: 668
Study 25201350 — intervention group
Group type: COMPARATOR
Intervention: Traditional wood fire
Number of subjects: 668
Study 23456498 — intervention group
Group type: EXPERIMENTAL
Intervention: Shudh™ colon cleanse (SCC)
Number of subjects: 133
Study 23456498 — intervention group
Group type: COMPARATOR
Intervention: HalfLytely(®) colon prep (HCP)
Number of subjects: 133
Study 21561497 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped smoking cessation intervention based on the transtheoretical model of change, involving 6-month implementation of recommendations from a Clinical Practice Guideline including brief motivational interviews, brief intervention, intensive intervention with pharmacotherapy, and reinforcing intervention.
Number of subjects: 2827
Study 21561497 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 2827
Study 21561497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2827
Study 19388915 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing
Number of subjects: 48
Study 19388915 — intervention group
Group type: COMPARATOR
Intervention: No Packing
Number of subjects: 48
Study 16686908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis treatment for migraine
Number of subjects: 141
Study 15462110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 80
Study 15462110 — intervention group
Group type: COMPARATOR
Intervention: Dietary therapy alone
Number of subjects: 80
Study 11208680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 40
Study 11208680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8989010 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of hetastarch solution
Number of subjects: 40
Study 8989010 — intervention group
Group type: COMPARATOR
Intervention: 1000 mL of lactated Ringer's solution
Number of subjects: 40
Study 7655330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day ground flaxseed
Number of subjects: 13
Study 7655330 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 13
Study 2106401 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (750 mg)
Number of subjects: 21
Study 2106401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (600 mg)
Number of subjects: 21
Study 2106401 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide (50 mg)
Number of subjects: 21
Study 346257 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg per day) for 7 days
Number of subjects: 67
Study 346257 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 67
Study 30740221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiology test ordering practices
Number of subjects: 1731
Study 30740221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiology test results
Number of subjects: 1731
Study 30740221 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional microbiology testing
Number of subjects: 1731
Study 26696034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention delivered face to face by a specialized HF nurse, including viewing a DVD and verbal discussion supported by a written manual.
Number of subjects: 200
Study 26696034 — intervention group
Group type: COMPARATOR
Intervention: Usual education (control group).
Number of subjects: 200
Study 26696034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention.
Number of subjects: 200
Study 26372383 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine along with atazanavir/ritonavir (ATV/r)
Number of subjects: 328
Study 26372383 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (DRV/r)
Number of subjects: 328
Study 26372383 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir (RAL)
Number of subjects: 328
Study 24795227 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendly algorithm for anaphylaxis case definition
Number of subjects: 40
Study 24795227 — intervention group
Group type: COMPARATOR
Intervention: Standard case definition for anaphylaxis
Number of subjects: 40
Study 21969227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 40 mg single dose
Number of subjects: 0
Study 21969227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg daily maintenance dose
Number of subjects: 0
Study 21969227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (various doses: 5, 10, 20, or 40 mg single doses; 0.5, 1, or 2.5 mg once daily)
Number of subjects: 0
Study 21969227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (various doses)
Number of subjects: 0
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin (HB) target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin saturation percentage (TSAT %) target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis KT/V target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis KT/V target maintenance
Number of subjects: 540
Study 19852833 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin dose
Number of subjects: 540
Study 17443852 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics + neomycin + mechanical bowel preparation (MBP)
Number of subjects: 92
Study 17443852 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation only
Number of subjects: 92
Study 17443852 — intervention group
Group type: COMPARATOR
Intervention: Neomycin + mechanical bowel preparation (MBP)
Number of subjects: 92
Study 17443852 — intervention group
Group type: COMPARATOR
Intervention: Synbiotics + neomycin without mechanical bowel preparation (MBP)
Number of subjects: 92
Study 14995924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg daily for 10 days
Number of subjects: 80
Study 14995924 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 75 mg daily for 10 days
Number of subjects: 80
Study 12000585 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 0
Study 9127395 — intervention group
Group type: EXPERIMENTAL
Intervention: AOO pacing (rate 80)
Number of subjects: 11
Study 9127395 — intervention group
Group type: EXPERIMENTAL
Intervention: DOO pacing in the right ventricular apex (AV delay 100 ms)
Number of subjects: 11
Study 9127395 — intervention group
Group type: EXPERIMENTAL
Intervention: DOO pacing in the right ventricular outflow tract
Number of subjects: 11
Study 9127395 — intervention group
Group type: EXPERIMENTAL
Intervention: DOO pacing at both right ventricular sites simultaneously
Number of subjects: 11
Study 9127395 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 11
Study 8458042 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 141
Study 8458042 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 141
Study 8458042 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 141
Study 8458042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 3540032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 5 mg
Number of subjects: 120
Study 3540032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 120
Study 3540032 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 120
Study 3540032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28413900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + medication
Number of subjects: 88
Study 28413900 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 88
Study 30110009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma therapy
Number of subjects: 100
Study 30110009 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 100
Study 30110009 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint-therapy (aroma therapy + music intervention)
Number of subjects: 100
Study 30110009 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular post-surgical nursery)
Number of subjects: 100
Study 28181167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 36
Study 28181167 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control group
Number of subjects: 36
Study 25322165 — intervention group
Group type: COMPARATOR
Intervention: Oral terbinafine
Number of subjects: 53
Study 25322165 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser treatment
Number of subjects: 53
Study 25322165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Oral terbinafine + Long-pulsed Nd:YAG laser)
Number of subjects: 53
Study 22301569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal irrigation with saline
Number of subjects: 109
Study 22301569 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (Control)
Number of subjects: 109
Study 20142584 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening in the United States
Number of subjects: 0
Study 20142584 — intervention group
Group type: COMPARATOR
Intervention: PSA screening in ERSPC-Rotterdam
Number of subjects: 0
Study 20142584 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA test sensitivity for nonpalpable local-or regional-stage cancers (stage T1M0) in the United States
Number of subjects: 0
Study 20142584 — intervention group
Group type: COMPARATOR
Intervention: PSA test sensitivity for nonpalpable local-or regional-stage cancers (stage T1M0) in ERSPC-Rotterdam
Number of subjects: 0
Study 17624052 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated catheter with 50 mL/d of normal saline solution as a continuous infusion
Number of subjects: 246
Study 16291713 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of prochlorperazine
Number of subjects: 0
Study 16291713 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of prochlorperazine, twice daily
Number of subjects: 0
Study 16291713 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet of prochlorperazine
Number of subjects: 0
Study 12780953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led weaning (n = 25)
Number of subjects: 50
Study 12780953 — intervention group
Group type: COMPARATOR
Intervention: Registrar-led weaning (n = 23)
Number of subjects: 50
Study 10442380 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus calcium folinate plus radiotherapy
Number of subjects: 0
Study 7769597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 1.0 mg (n = 30)
Number of subjects: 60
Study 7769597 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal diamorphine 0.75 mg (n = 30)
Number of subjects: 60
Study 1827709 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic exercise (21% O2)
Number of subjects: 6
Study 1827709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (13.3 +/‐ 0.3% O2)
Number of subjects: 6
Study 1827709 — intervention group
Group type: COMPARATOR
Intervention: Comparison between normoxic and hypoxic exercise
Number of subjects: 6
Study 6456960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 week physical training program
Number of subjects: 50
Study 6456960 — intervention group
Group type: COMPARATOR
Intervention: No supervised physical activity
Number of subjects: 50
Study 30557279 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 96
Study 30557279 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 96
Study 30557279 — intervention group
Group type: COMPARATOR
Intervention: Written-pictorial instruction
Number of subjects: 96
Study 28610960 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (heat pain 46‐47°C/cold pain 7‐8°C)
Number of subjects: 79
Study 28610960 — intervention group
Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (heat 40‐41°C/cold 20‐21°C)
Number of subjects: 79
Study 28610960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Noxious and Innocuous TS)
Number of subjects: 79
Study 25916658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 25916658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24129553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed orocutaneous stimulation during gavage feedings
Number of subjects: 22
Study 24129553 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stimulation)
Number of subjects: 22
Study 22452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful self-focus
Number of subjects: 40
Study 22452758 — intervention group
Group type: COMPARATOR
Intervention: Ruminative self-focus
Number of subjects: 40
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: senofilcon A lenses
Number of subjects: 33
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPCOF, NIBUT, and OSDI
Number of subjects: 33
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPCOF Sum plus NIBUT and OSDI
Number of subjects: 33
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: LWE
Number of subjects: 33
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal hyperaemia
Number of subjects: 33
Study 19668016 — intervention group
Group type: EXPERIMENTAL
Intervention: NIBUT
Number of subjects: 33
Study 17667723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) 3 x 10 colony-forming units, twice daily for 4 weeks
Number of subjects: 29
Study 17667723 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 weeks
Number of subjects: 29
Study 17667723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 29
Study 17667723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15363567 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral ethanol ablation of the prostate (TEAP) using ProstaJect device, average ethanol injected 14 ml.
Number of subjects: 115
Study 15363567 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral ethanol ablation of the prostate (TEAP)
Number of subjects: 115
Study 11442862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 11442862 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 9740115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 147
Study 9740115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 7979340 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of sucrose
Number of subjects: 52
Study 7979340 — intervention group
Group type: COMPARATOR
Intervention: 4.34 g of saccharin
Number of subjects: 52
Study 2806714 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of atenolol (100 mg)
Number of subjects: 0
Study 2806714 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of atenolol (100 mg)
Number of subjects: 0
Study 241272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfatesine
Number of subjects: 0
Study 241272 — intervention group
Group type: COMPARATOR
Intervention: Pentothal
Number of subjects: 0
Study 31665001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education through weblogs
Number of subjects: 98
Study 27346074 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg orally) on the day before, the day, and the day after TUR-BT
Number of subjects: 148
Study 27346074 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 148
Study 27346074 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg orally)
Number of subjects: 148
Study 26327130 — intervention group
Group type: EXPERIMENTAL
Intervention: AJM300 (960 mg)
Number of subjects: 102
Study 26327130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 23439259 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7009 (vaniprevir) + PegIFN + ribavirin
Number of subjects: 40
Study 23439259 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PegIFN + ribavirin
Number of subjects: 40
Study 20947097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung lavage with dilute bovine surfactant (two 15‐mL/kg aliquots)
Number of subjects: 65
Study 20947097 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 65
Study 20947097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung lavage with dilute bovine surfactant
Number of subjects: 65
Study 20947097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung lavage with dilute surfactant
Number of subjects: 65
Study 18507545 — intervention group
Group type: EXPERIMENTAL
Intervention: 8F leads
Number of subjects: 714
Study 18507545 — intervention group
Group type: COMPARATOR
Intervention: 7F leads
Number of subjects: 714
Study 18507545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 714
Study 16892434 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiot ePTFE covered stent
Number of subjects: 400
Study 16892434 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 400
Study 14570785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 microg kg(‐1)
Number of subjects: 13
Study 14570785 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg kg(‐1)
Number of subjects: 13
Study 10971827 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy for 16 or 32 weeks
Number of subjects: 162
Study 10971827 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after 16 weeks
Number of subjects: 162
Study 10971827 — intervention group
Group type: COMPARATOR
Intervention: Prolonged treatment for another 16 weeks
Number of subjects: 162
Study 8627059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose didanosine (ddI) 375 mg twice daily
Number of subjects: 73
Study 8627059 — intervention group
Group type: COMPARATOR
Intervention: Low-dose didanosine (ddI) 100 mg twice daily
Number of subjects: 73